Arbutus Biopharma (ABUS) Current Deferred Revenue (2010 - 2025)

Arbutus Biopharma has disclosed Current Deferred Revenue across 13 years of filings, most recently posting $6.8 million for Q1 2025.

• Current Deferred Revenue for Q1 2025 came in at $6.8 million, down 41.47% year-over-year; the trailing twelve-month figure through Mar 2025 was $6.8 million (down 41.47% YoY), and the FY2024 annual result was $7.6 million, down 35.79% from the prior year.
• Current Deferred Revenue came in at $6.8 million for Q1 2025 at Arbutus Biopharma, down from $7.6 million in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $23.3 million in Q1 2022 to a low of $6.8 million in Q1 2025.
• The 4-year median for Current Deferred Revenue is $12.1 million (2023), against an average of $13.4 million.
• Across the five-year window, Current Deferred Revenue fell 9.7% in 2023 and plunged 41.47% in 2025, its largest moves.
• Arbutus Biopharma's Current Deferred Revenue stood at $16.5 million in 2022, then slipped by 28.35% to $11.8 million in 2023, then slumped by 35.79% to $7.6 million in 2024, then decreased by 10.73% to $6.8 million in 2025.
• The last three Current Deferred Revenue figures came in at $6.8 million (Q1 2025), $7.6 million (Q4 2024), and $10.9 million (Q3 2024), per Business Quant data.